Biogen

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO says can "understand the concept of time and how you change, from cradle to grave.

Beyond speed, AI has also helped reduce costs. Conventional methods required nearly $35,000 per genome analysis, but AI-driven models running on GPUs have lowered the cost to under $2,000, making high-quality genomic research more accessible.

Iktos, a global leader in AI-driven drug discovery, has secured a prestigious €2.5 million grant from the European Innovation Council (EIC) Accelerator to advance its AI and robotics synthesis automation technology.

Biotechnology innovations are revolutionizing healthcare with AI, data science, and automation, leading to more precise and personalized treatments.

This new approach, powered by a specialised protein large language model, predicts the most effective protein variants while using 99% less data than traditional methods.

As the CEO of Karyon Bio, Thirunagari introduced the company's ground breaking Digital Liver initiative, an AI-powered approach to tackling Metabolic Dysfunction-Associated Steatotic Liver Disease (MA